A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma
Learn more about:
Related Clinical Trial
A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma
Phase I Study of IGM-8444 as a Single Agent and in Combination in Subjects With Relapsed and/or Refractory Solid Cancers
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
IPI-926 Extension Protocol for Continuation of Treatment With IPI-926
A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas
Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma – Phase 1b Trial
Proton Beam Therapy for Chondrosarcoma
Low Grade Chondrosarcoma Versus Enchondroma
AG-120 in People With IDH1 Mutant Chondrosarcoma
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Low and Inter-mediate Grade Chondrosarcoma of the Skull Base
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas